李 新,孙万军,靳凤艳.20例存活7年以上多发性骨髓瘤患者临床观察[J].肿瘤学杂志,2014,20(7):574-577. |
20例存活7年以上多发性骨髓瘤患者临床观察 |
Clinical Analysis of 20 Cases with Multiple Myeloma Surviving More Than 7 Years |
投稿时间:2014-03-21 |
DOI:10.11735/j.issn.1671-170X.2014.07.B010 |
|
|
中文关键词: 多发性骨髓瘤 生存期 预后 |
英文关键词:multiple myeloma survival prognosis |
基金项目: |
|
摘要点击次数: 2986 |
全文下载次数: 847 |
中文摘要: |
摘 要:[目的] 分析生存期大于7年的多发性骨髓瘤患者的临床特点。[方法] 回顾性分析了20例存活7年以上的多发性骨髓瘤患者的一般情况、临床特征、治疗与预后。[结果] 7年存活率11.1%(20/180),10例(50.0%)患者在疾病进展期出现髓外瘤细胞的浸润。20例患者共接受了中位数28(15~41)个周期的化疗,复发患者接受了以硼替佐米为主的化疗方案、DECP方案、来那度胺、三氧化二砷及脂质体阿霉素治疗。20例患者的中位生存期为91(84~120)个月,至随访结束,仍有11例患者存活。[结论]多发性骨髓瘤的预后除与肿瘤负荷、宿主因素、肿瘤生物学等有关外,还与治疗措施及治疗反应密切相关。 |
英文摘要: |
Abstract:[Purpose] To investigate the clinical characteristics of multiple myeloma(MM) patients surviving more than 7 years. [Methods] General condition,clinical features,treatment and prognosis of 20 cases with MM surviving more than 7 years were analyzed retrospectively.[Results] The 7-year survival rate was 11.1%(20/180). There were 10(50.0%)patients occurred extramedullary plasmacytomas during the progression of the diseases. The 20 patients had received the median of 28(15~41)cycles of chemotherapy. The relapsed MM patients had received chemotherapy based with bortezomib,DECP regimen,lenalidomide,Arsenic trioxide and pegylated liposomal doxorubicin. The median survival was 91(84~120)months. There were 11 patients still alive at the end of follow-up. [Conclusion] Besides tumor burden,host factors and tumor biology,the prognosis of MM correlates with the treatment modality and response to therapy. |
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|